Literature DB >> 25716732

Novel recombinant anti-HER2/neu immunotoxin: design and antitumor efficiency.

E A Sokolova1, T A Zdobnova, O A Stremovskiy, I V Balalaeva, S M Deyev.   

Abstract

The novel HER2/neu-specific recombinant immunotoxin 4D5scFv-PE40 consisting of 4D5scFv antibody (targeting module) and Pseudomonas exotoxin A fragment (effector module) combined in a single polypeptide chain via a flexible linker has been expressed and purified. This immunotoxin conserves specificity and affinity that are characteristics of the parental antibody 4D5scFv and exhibits selective and strong cytotoxic effect against cancer cells overexpressing HER2/neu receptor. The results of the experiments both in vitro (in cell cultures) and in vivo (in tumor-bearing animals) demonstrate high potential of 4D5scFv-PE40 for targeted therapy of tumors overexpressing HER2/neu.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25716732     DOI： 10.1134/S0006297914120128

Source DB:  PubMed          Journal:  Biochemistry (Mosc)        ISSN： 0006-2979            Impact factor:   2.824


  9 in total

Review 1.  Improved Protein Toxin Delivery Based on ATTEMPTS Systems.

Authors:  Yingzhi Chen; Meng Zhang; Kyoung Ah Min; Huiyuan Wang; Meong Cheol Shin; Feng Li; Victor C Yang; Yongzhuo Huang
Journal:  Curr Drug Targets       Date:  2018-02-19       Impact factor: 3.465

2.  Far-red fluorescent cell line for preclinical study of HER2-targeted agents.

Authors:  I V Balalaeva; E A Sokolova; A A Brilkina; S M Deyev; R V Petrov
Journal:  Dokl Biochem Biophys       Date:  2016-01-05       Impact factor: 0.788

3.  Cytotoxicity of targeted HER2-specific phototoxins based on flavoprotein miniSOG is determined by the rate of their internalization.

Authors:  O N Shilova; G M Proshkina; A V Ryabova; S M Deyev; R V Petrov
Journal:  Dokl Biochem Biophys       Date:  2017-09-02       Impact factor: 0.788

4.  Spheroids of HER2-Positive Breast Adenocarcinoma for Studying Anticancer Immunotoxins In Vitro.

Authors:  I V Balalaeva; E A Sokolova; A D Puzhikhina; A A Brilkina; S M Deyev
Journal:  Acta Naturae       Date:  2017 Jan-Mar       Impact factor: 1.845

5.  HER2-Specific Targeted Toxin DARPin-LoPE: Immunogenicity and Antitumor Effect on Intraperitoneal Ovarian Cancer Xenograft Model.

Authors:  Evgeniya A Sokolova; Olga N Shilova; Daria V Kiseleva; Alexey A Schulga; Irina V Balalaeva; Sergey M Deyev
Journal:  Int J Mol Sci       Date:  2019-05-15       Impact factor: 6.208

Review 6.  Natural and Designed Toxins for Precise Therapy: Modern Approaches in Experimental Oncology.

Authors:  Olga Shilova; Elena Shramova; Galina Proshkina; Sergey Deyev
Journal:  Int J Mol Sci       Date:  2021-05-07       Impact factor: 5.923

7.  Recombinant Immunotoxin 4D5scFv-PE40 for Targeted Therapy of HER2-Positive Tumors.

Authors:  E A Sokolova; O A Stremovskiy; T A Zdobnova; I V Balalaeva; S M Deyev
Journal:  Acta Naturae       Date:  2015 Oct-Dec       Impact factor: 1.845

8.  HER2-specific recombinant immunotoxin 4D5scFv-PE40 passes through retrograde trafficking route and forces cells to enter apoptosis.

Authors:  Evgeniya Sokolova; Evgeniy Guryev; Andrey Yudintsev; Vladimir Vodeneev; Sergey Deyev; Irina Balalaeva
Journal:  Oncotarget       Date:  2017-03-28

9.  The Effect of the Targeted Recombinant Toxin DARPin-PE40 on the Dynamics of HER2-Positive Tumor Growth.

Authors:  E A Sokolova; G M Proshkina; O M Kutova; I V Balalaeva; S M Deyev
Journal:  Acta Naturae       Date:  2017 Jul-Sep       Impact factor: 1.845
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.